secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0000950170-21-003291
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam gets FDA clearance for first base editing IND (BEAM-101); Q3 net loss $28.1M, cash $933.4M
--------------------------------------------------------------------------------

- FDA cleared IND for BEAM-101 (sickle cell disease); first open IND for base editing.
- Beam initiated IND-enabling studies for BEAM-102 (Makassar base editing for sickle cell).
- Q3 net loss $28.1M ($0.42/share); R&D $54.6M, G&A $15.8M.
- Cash, equivalents & securities $933.4M as of Sep 30, 2021, up from $299.7M at Dec 31, 2020.
- Non-exclusive license to Sana for Cas12b for $50M upfront; potential milestones/royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017021003291/0000950170-21-003291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017021003291/beam-20211105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-003291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer